IGC PHARMA, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- IGC PHARMA, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $1.04M, a 23.84% increase year-over-year.
- IGC PHARMA, INC. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $351.00K, a 56.40% decline year-over-year.
- IGC PHARMA, INC. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $1.03M, a 198.84% increase year-over-year.
- IGC PHARMA, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $3.11M, a 745.65% increase year-over-year.
- IGC PHARMA, INC. stock issued during period, value, new issues for fiscal 2025 was $4.25M, a 40.47% increase from fiscal 2024.
- IGC PHARMA, INC. stock issued during period, value, new issues for fiscal 2024 was $3.03M, a 2838.83% increase from fiscal 2023.
- IGC PHARMA, INC. stock issued during period, value, new issues for fiscal 2023 was $103.00K, a 97.52% decline from fiscal 2022.
- IGC PHARMA, INC. stock issued during period, value, new issues for fiscal 2022 was $4.14M, a 70.72% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $1.04M 10-Q · filed 2026-08-14 | $5.53M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $351.00K 10-Q · filed 2026-05-15 | $5.33M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.03M derived: 10-KT 9 month − 10-Q 6 month · filed 2026-03-18 | $5.79M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | $3.11M 10-Q · filed 2025-11-14 | $5.10M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $839.00K 10-Q · filed 2026-08-14 | $2.36M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $805.00K 10-Q · filed 2026-05-15 | $4.25M 10-KT · filed 2026-03-18 |
| 2024-12-31 | $345.00K 10-Q · filed 2025-02-14 | $3.39M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-09-30 | $368.00K 10-Q · filed 2025-11-14 | $3.04M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $2.51M 10-Q · filed 2025-08-14 | $5.53M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $167.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-27 | $3.03M 10-K · filed 2025-06-27 |
| 2023-12-31 | $0.00 10-Q · filed 2025-02-14 | |
| 2023-09-30 | $2.86M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-24 | $103.00K 10-K · filed 2024-06-24 |
| 2022-12-31 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-14 | |
| 2022-09-30 | $104.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-07 | $4.14M 10-K · filed 2023-07-07 |
| 2021-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-14 | $18.20M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-09-30 | $3.42M 10-Q · filed 2022-11-01 | $18.20M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $726.00K 10-Q · filed 2022-08-05 | $14.78M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $14.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-23 | $14.16M 10-K · filed 2022-06-23 |
| 2020-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-02-16 | |
| 2020-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-11-20 | |
| 2020-06-30 | $100.00K 10-Q · filed 2020-08-19 | |
| 2019-03-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-07-13 | $28.51M 10-K · filed 2020-07-13 |
| 2018-12-31 | $23.60M 10-Q · filed 2020-02-10 | |
| 2018-09-30 | $4.73M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $134.00K 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $3.49M 10-K · filed 2019-06-14 | |
| 2017-03-31 | $642.16K 10-K · filed 2018-06-21 | |
| 2016-09-30 | $204.74K 10-Q · filed 2016-11-21 | |
| 2016-06-30 | $25.67K 10-Q · filed 2016-08-16 | |
| 2016-03-31 | $332.05K 10-K · filed 2017-07-14 | |
| 2015-12-31 | $184.01K 10-Q · filed 2016-02-16 | |
| 2015-09-30 | $92.82K 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $55.11K 10-Q · filed 2015-08-14 | |
| 2014-09-30 | $58.80K 10-Q · filed 2014-11-13 | |
| 2014-03-31 | -$132.66K derived: 10-K 12 month − 10-Q 9 month · filed 2015-07-14 | $506.25K 10-K · filed 2015-07-14 |
| 2013-12-31 | $489.08K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-02-14 | |
| 2013-09-30 | $202.00K 10-Q · filed 2013-11-08 | |
| 2012-03-31 | $2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2014-07-15 | $3.55M 10-K · filed 2014-07-15 |
| 2011-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-16 | |
| 2011-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2011-11-18 | |
| 2011-06-30 | $582.12K 10-Q · filed 2011-08-18 | |
| 2011-03-31 | $1.76M 10-K · filed 2012-07-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |